摘要
目的探讨促肝细胞生长素联合还原型谷胱甘肽治疗肝衰竭患者的临床疗效。方法选取2019年1月至2021年1月我院收治的68例肝衰竭患者,随机分为研究组(n=34)与对照组(n=34)。对照组采用促肝细胞生长素静脉滴注治疗,研究组在对照组基础上采用还原型谷胱甘肽静脉滴注治疗。对比两组患者的凝血功能、肝功能、临床疗效及复发率。结果治疗前,两组的凝血功能和肝功能指标比较差异无统计学意义(P>0.05);治疗后,研究组的凝血功能和肝功能指标明显优于对照组(P<0.05)。研究组总有效率97.06%,明显高于对照组的79.41%(P<0.05)。随访6个月,研究组复发率为2.94%,明显低于对照组的17.65%(P<0.05)。结论促肝细胞生长素联合还原型谷胱甘肽治疗肝衰竭患者的临床疗效显著,可有效改善患者的肝脏功能,复发率低,药物安全性高,值得临床推广。
Objective To explore the clinical efficacy of hepatocyte growth promoting factors combined with reduced glutathione in the treatment of patients with liver failure.Methods 68 cases of patients with liver failure admitted to our hospital from January 2019 to January 2021 were randomly divided into study group(n=34)and control group(n=34).The control group was treated with intravenous infusion of hepatocyte growth promoting factors,and the study group was treated with intravenous infusion of reduced glutathione on the basis of the control group.The coagulation function,liver function,clinical efficacy and recurrence rate were compared between the two groups.Results Before treatment,no statistical difference was found in the indicators of coagulation function and liver function between the two groups(P>0.05);After treatment,the indicators of coagulation function and liver function in the study group were significantly better than those in the control group(P<0.05).The total effective rate of the study group was 97.06%,significantly higher than 79.41% of the control group(P<0.05).Following for 6 months,the recurrence rate of the study group was 2.94%,significantly lower than 17.65% of the control group(P<0.05).Conclusions Hepatocyte growth promoting factors combined with reduced glutathione in the treatment of patients with liver failure has significant clinical efficacy,and can effectively improve the liver function of patients,with lower recurrence rate and higher drug safety,which is worthy of clinical promotion.
作者
张金凤
魏素云
ZHANG Jinfeng;WEI Suyun(3^(rd)Department of Liver Diseases,Anyang Fifth People's Hospital,Anyang 455000,China)
出处
《临床医学工程》
2023年第3期351-352,共2页
Clinical Medicine & Engineering
关键词
促肝细胞生长素
还原型谷胱甘肽
肝衰竭
Hepatocyte growth promoting factor
Reduced glutathione
Liver failure
